The Nasodine Story

Nasodine® is the registered brand for a range of povidone-iodine (PVP-I) products developed for use in the upper respiratory tract. The Nasodine range is the result of more than 10 years of pharmaceutical R&D by Firebrick Pharma Ltd, an innovative Australian biopharmaceutical company.  The "Firebrick" name comes from the colour of PVP-I.

Nasodine Nasal Spray was the first innovation from Firebrick, and was originally developed as a treatment and preventative for the common cold.  Nasodine Nasal Spray has been  assessed in multiple independently-controlled human clinical trials. These trials show that Nasodine Nasal Spray is safe to use as recommended and support its effective use in a range of clinical settings. Nasodine Nasal Spray is backed by a growing list of peer-reviewed publications that are publicly available for review (see below). In addition, Firebrick Pharma owns multiple international patents on Nasodine Nasal Spray and the Nasodine® trademark is an internationally registered trademark owned by Firebrick Pharma. 

In January 2026, Firebrick introduced the first new addition to the Nasodine range: Nasodine Throat Spray, a 1% povidone-iodine formulation specifically designed for killing germs in the throat. Then in October 2026, Firebrick launched its third product in the Nasodine range: Nasodine Sinus Rinse, the world's first  antiseptic-powered nasal and sinus wash.

Firebrick Pharma co-founders Dr Stephen Goodall and Dr Peter Molloy

    Peer-reviewed Publications on Nasodine Nasal Spray:

    1. Polasek, T. M., & Friedland, P. L. (2025). Povidone-iodine nasal spray (Nasodine®) for the common cold: a randomized, controlled, double-blind, Phase III clinical trial. Frontiers in Medicine,12, 1565069. DOI:10.3389/fmed.2025.1565069 https://pubmed.ncbi.nlm.nih.gov/40538402

    2. Friedland, P. L., & Tucker, S. (2024). Phase II Trial of the Impact 0.5% Povidone‐Iodine Nasal Spray (Nasodine®) on Shedding of SARS‐CoV‐2. The Laryngoscope, 134(9), 3947-3952. DOI:10.1002/lary.31430 https://pubmed.ncbi.nlm.nih.gov/38554057

    3. Friedland, P. L., Polasek, T. M., & Topliss, D. (2024). Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone‐iodine nasal spray (Nasodine). In International Forum of Allergy & Rhinology (Vol. 14, No. 9). DOI:10.1002/alr.23389 https://pubmed.ncbi.nlm.nih.gov/38869489

    4. Hale, S. J. et al. (2023). In vitro Nasodine can be an effective antibiofilm agent for biofilms that may cause CRS. The Laryngoscope, 133(10), 2490-2495. https://doi.org/10.1002/lary.30558

    5. Friedland, P. et al. (2022). In vivo (human) and in vitro inactivation of SARS-CoV-2 with 0.5% povidone-iodine nasal spray. Australian Journal of Otolaryngology. 2022, 5, (0), pp. 1-9 https://www.theajo.com/article/view/4466/html

    6. Ramezanpour, M. et al. (2020). In vitro safety evaluation of a povidone‐iodine solution applied to human nasal epithelial cells. InInternational forum of allergy & rhinology(Vol. 10, No. 10, pp. 1141-1148). https://doi.org/10.1002/alr.22575